RAS Webinar Videos
Watch videos of RAS-related lectures from past events.
As part of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's History of Biology and Medicine lecture series, Dr. Frank McCormick summarizes four decades of RAS research and explains the role of RAS proteins in human diseases.
Dr. Pasi A Jänne, "A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRAS G12C inhibitor, in advanced solid tumors"
Dr. Pasi A Jänne presents clinical trial data of MRTX849, which specifically targets KRAS G12C mutant tumors.
Dr. Alan Ho discusses clinical trial data of tipifarnib, a drug that targets HRAS
The NCI RAS Initiative was featured on National Public Radio on March 9, 2018. Photo credit: Richard Harris/NPR Used with permission.
At the Annual Meeting of the American Association for Cancer Research, Frank McCormick, leader of the NCI RAS Initiative, summarizes recent RI activities.
Bert Vogelstein reflects on why we can cure cancer in mice but not so well in people, and on the sources of mutations in cancer.
As drugs that attack RAS directly become available, cancers will inevitably develop resistance. What Charles Sawyers tells us about resistance mechanisms in prostate cancer gives us hope that resistance to RAS therapies can be overcome.
All the scientific presentations from the 2015 Annual Meeting of the American Association for Cancer Research in Philadelphia, USA that are available for viewing without charge may now be found on the AACR web site.
Dr. Matt Holderfield of the Frederick National Lab describes the development of multiple drug screening platforms targeting KRAS in the NCI RAS Initiative. April 21, 2015 at the AACR Annual Meeting, Philadelphia, USA.
Dr. Michael Stratton of the Welcome Trust Sanger Institute, Cambridge, UK describes new insights into the mutational processes that drive cancers. (Dr. Stratton's sciencific remarks begin five minutes into the video.) April 19, 2015 at the AACR Annual Meeting, Philadelphia USA.
Dr. Susan Bates of the NCI's Developmental Therapeutics Branch and Dr. Frank McCormick, science advisor to the NCI RAS Initiative, describe the impact of RAS mutations on human health, and new information on regulation of RAS signaling. February 10, 2015 at the National Cancer Institute, Bethesda, Maryland
Dr. Frank McCormick describes recent experiments to understand KRAS signaling in cancer at the AACR Annual Meeting, April 5, 2014, San Diego, California USA
2011: Structural Aspects of RAS GTPases
Dr. Alfred Wittinghofer explains how solving the three-dimensional structure of RAS and other G-proteins allowed him to understand the conserved mechanism by which G-proteins can act as switches. June 19, 2011
In the second part of Dr. Wittinghofer's talk he explains the link between GTPases and disease. June 19, 2011